[Long-term course in asymptomatic carriers of HBsAg in an area of low prevalence of hepatocarcinoma].
Data provided by 51 voluntary blood donors identified as asymptomatic HBsAg carriers five to ten years (mean = 7.5 years) before their inclusion in the study are analysed towards their long-term evolution. HBsAg clearance was estimated 2.5% yearly and 83.9% of those remaining positive showed the classical non-replicative serological pattern; another 12.9% were negative for both HBeAg-Anti HBe (seroconversion window?), one of them presenting raised ASAT-ALAT levels and enhanced histological activity (lobular chronic hepatitis). Neither alpha-fetoprotein seric levels (RIA) nor liver ultrasonography demonstrated hepatocellular carcinoma suspicion signs in 35 HBsAg positive cases to this methods; ASAT-ALAT levels raised over two fold the normal superior limit in only 11.4%, and neither aggressive chronic liver disease nor hepatocyte dysplasia was showed in 17 biopsied cases (70.6% normal; 23.6% chronic reactive or chronic persistent hepatitis; 5.8% chronic lobular hepatitis). One out of five patients biopsied with a seven years interval showed histologic worsening.
Jmelnitzky
A
A
Universidad Nacional de la Plata, Argentina.
Basualdo
J A
JA
Castelletto
R
R
Mon
J C
JC
Belloni
P
P
Rondina
A
A
García
C
C
D001782:Blood Donors; D006528:Carcinoma, Hepatocellular / Q000209:etiology*; D002353:Carrier State / Q000276:immunology*; D006509:Hepatitis B / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006513:Hepatitis B e Antigens / Q000032:analysis; D006801:Humans; D008113:Liver Neoplasms / Q000209:etiology*; D011446:Prospective Studies; D000637:Transaminases / Q000097:blood; D000509:alpha-Fetoproteins / Q000032:analysis
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D000509:alpha-Fetoproteins; D000637:Transaminases
Evolución alejada en portadores asintomáticos HBsAg (PA-HBsAg) en un area de baja prevalencia de hepatocarcinoma.